New Study Finds Clopidogrel Superior to Aspirin for Long-Term Maintenance Following Complex Stent Procedures

New research from SCAI 2026 shows clopidogrel monotherapy reduces risks better than aspirin for patients following complex cardiovascular stent procedures.

By: AXL Media

Published: Apr 25, 2026, 9:03 AM EDT

Source: Information for this report was sourced from EurekAlert!

A Paradigm Shift in Post-Surgical Cardiovascular Maintenance

Clinical data presented at the SCAI 2026 Scientific Sessions in Montreal has challenged the long-standing medical reliance on aspirin for patients who have undergone percutaneous coronary intervention. According to researchers, transitioning to clopidogrel monotherapy after an initial year of dual antiplatelet therapy provides a more effective shield against both clotting and bleeding. The study focused on a significant patient cohort who remained event-free during their first year of recovery, suggesting that the traditional guidelines favoring aspirin may need to be re-evaluated to improve long-term survival and health outcomes.

Evolution of Antiplatelet Therapy and Stent Recovery Protocols

The standard medical response for patients receiving drug-eluting stents has historically involved a rigorous period of dual antiplatelet therapy to prevent thrombosis as the artery heals. This balancing act requires clinicians to weigh the necessity of preventing dangerous clots against the inherent danger of inducing severe internal bleeding. While aspirin has functioned as the global baseline for secondary prevention for decades, the emergence of clopidogrel as a viable alternative offers a more nuanced approach to chronic maintenance, particularly as the immediate risks of the surgical site decrease over time.

Methodology and Demographic Scope of the Beijing Clinical Trial

Conducted at Fuwai Hospital in Beijing, the study analyzed the outcomes of 5,664 patients who successfully completed a one-year regimen of dual antiplatelet therapy without complications. The demographic breakdown revealed a predominantly male participation rate of 75.8 percent, with a significant portion of the group classified as having a high risk of bleeding or a history of complex coronary procedures. Researchers utilized the net adverse clinical events metric to track major cardiovascular incidents, including stroke and myocardial infarction, alongside clinically relevant bleeding episodes over a three-year observation period.